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Introduction
Chromodomain-helicase-DNA-binding 
protein 1 (CHD1) is an ATP-dependent 
chromatin remodeler involved in gene 
transcription and organismal 
development [1]. Homozygous CHD1 
deletion leads to genomic instability as 
well as cell phenotypic alterations and is 
the second most common deletion 
found in human prostate cancer (PCa) 
[2-4]. KDM1/3/4 protein family are 
histone demethylases that target H3K9 
and H3K36 [5]. High expression of 
KDMs can lead to the downregulation of 
H3K9me3 and subsequent abnormal 
gene activation, promoting 
tumorigenesis in prostate cancer (Fig. 1) 
[6, 7]. ML324 is a small-molecule 
selective inhibitor of KDM4s which 
reduces PCa cell proliferation [8-10]. 
Here, we study the crosstalk between 
CHD1 and KDM4 in PCa. 
Conclusions
As a chromatin remodeler, CHD1 has 
been found to be involved in transcription 
regulation by reading H3K4me3. Here, 
our study uncovered a novel function of 
CHD1 in modulating KDMs. CHD1 loss 
inhibits KDM4A/D while promoting
KDM1A and KDM3A, resulting in the 
maintenance of H3K9me3 levels. Future 
studies will focus on exploring this 
relationship as well as the identification of 
target genes and downstream pathways 
of the CHD1-KDM axis to better 
understand their function in PCa
development and progression. 
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Fig. 3 ML324, a selective KDM4 inhibitor, was found to 
be the most sensitive compound in WT vs CHD1 
knockout PCa cell lines through epigenetic compound 
screening (A) and IC50 analyses (B-C)
Results
Through epigenetics compound library 
screening, ML324, a small-molecule 
selective inhibitor of KDM4, ranked as 
the most sensitive compound in WT 
versus CHD1 knockout LNCaP cells 
(Fig. 3A). IC50 analyses in multiple PCa
cell lines with or without CHD1 deletion 
confirmed that CHD1 loss makes PCa
cells less sensitive to KDM4 inhibitor 
ML324 (Fig. 3B-C). Mechanistically, we 
found that CHD1 deletion reduces the 
expression of KDM4A and KDM4D both 
in vitro (Fig. 4) and in vivo (Fig. 5). 
KDM4A and KDM4D regulate the 
demethylation of H3K9, but 
trimethylation levels of H3K9 did not 
change with CHD1 loss in vivo (Fig. 5). 
However, CHD1 deletion upregulates 
KDM1A and KDM3A (Fig. 6), which also 
regulates the demethylation of H3K9. 
This may compensate for the reduced 
KDM4A/D, resulting in the maintenance 
of H3K9me3 levels.
Methods
Epigenetics compound library screening 
was performed using LNCaP WT cells 
and isogeneic CHD1 knockout cells, cell 
viability was then measured using 
CellTiter-Glo® Luminescent Cell 
Viability Assay. The small compounds 
were ranked based on the sensitivity in 
WT versus CHD1 knockout cells. For 
top candidates, the IC50 was 
determined by measuring cell viability in 
multiple PCa cell lines. RNA levels were 
measured using qPCR and RNA array. 
ChIP-seq was used to assess CHD1 
regulation of KDM4A and KDM4D. 
Protein expression and histone markers 
were measured by Western Blot and 
immunohistochemistry. 
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Fig. 4 CHD1 regulates KDM4A and KDM4D levels. 
qPCR shows mRNA expression in LNCaP WT vs CHD1 
KO cells (A). ChIP-seq shows that CHD1 binds to the 
promoter regions of KDM4A and KDM4D (B). Western 
Blot shows decreased KDM4A and KDM4D protein 
levels in CHD1 KO lines (C). TCGA database shows 
that KDM4A and CHD1 levels are highly correlated.
Fig. 5 Immunohistochemistry of DU145 WT and CHD1 
knockout tumors show a decrease in KDM4A and 
KDM4D, however no apparent change in H3K9me3
Fig. 2 Epigenetics compound library screening process 
to determine drug responsiveness in CHD1 loss 
prostate cancer.
Fig. 1  Alteration of 
H3K9 methylation 











































Fig. 7  Proposed mechanism for CHD1-KDM axis.
A
B
Fig. 6 KDM1A and KDM3A RNA levels are upregulated 
upon CHD1 deletion, show via RNA microarray.
